Chao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chao Zhang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Wen-Zhao Zhong
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
9 shared publications - Yi-Long Wu
Southern Medical University
8 shared publications Song Dong
Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
5 shared publicationsXue-Ning Yang
Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
5 shared publicationsJian Su
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
4 shared publicationsQing Zhou
Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China
4 shared publications
Latest Publications
- Open Access
- 28 May 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 96, 103994
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
- 28 May 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 96, 103994
Open AccessNeoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
- Open Access
- 1 September 2022
- Published by Elmer Press, Inc. in Clinical Infection and Immunity
- Vol. 7 (2) , 37-48
Transfer Learning-Based Model for Automated COVID-19 Detection Using Computerized Tomography Scan Graph
- 1 September 2022
- Published by Elmer Press, Inc. in Clinical Infection and Immunity
- Vol. 7 (2) , 37-48
Open AccessTransfer Learning-Based Model for Automated COVID-19 Detection Using Computerized Tomography Scan Graph
- 1 March 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 109 (3) , 856-863
Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers
- 1 March 2020
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 109 (3) , 856-863
Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers
- 1 November 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (11) , 1912-1923
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma
- 1 November 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (11) , 1912-1923
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , e234-e236
Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib
- 1 October 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (10) , e234-e236
Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib
- Open Access
- 31 July 2019
- Published by Wiley in Thoracic Cancer
- Vol. 10 (9) , 1827-1833
Drainage tube hole suture improvement: Removal‐free stitches
Surgical method improvements aim to optimize the patient experience. The problem of healing of the drainage tube hole has not received attention and is of concern because it can plague patient recovery. In this article we report on how we have improved the method of suturing the drainage tube hole and explore the safety and effectiveness of this method. Between December 2017 to August 2018, 102 patients underwent thoracoscopic lung resection (single port or single utility port) using different methods of suturing drainage tube holes. The intervention group received improved methods with subcuticular and intradermal suture and removal‐free stitches, whilst the control group received a conventional mattress suture and fixed chest tube. A preset line was left to tie knots and close the hole after the removal of the chest tube. The stitches were removed 7–12 days after surgery. The baseline clinical features of the patients were subsequently analyzed. The objective and subjective conditions of scars were evaluated using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) at one month after surgery. The intervention group (n = 71) and control group (n = 31) had balanced baseline clinical characteristics. There were no significant differences between the two groups in terms of three‐day postoperative pain and postoperative hospital stay. In the intervention group, three patients (4.23%) had wound splitting that required re‐suturing, which was better than five patients (16.13%) in the control group (P < 0.05). The incidence of pleural fluid outflow, wound infection, post‐removal pneumothorax, chest tube prolapse and incisional hernia were not different between the two groups. We conclude that the objective and subjective evaluation results of scars were significantly different between the two groups (P < 0.05), and the experimental group was superior to the control group. A balanced result between aesthetic appearance and safety as regards video‐assisted thoracic surgery can be achieved through the chest tube hole improved suture method. This method also improves the patient's recovery experience.
- 31 July 2019
- Published by Wiley in Thoracic Cancer
- Vol. 10 (9) , 1827-1833
Open AccessDrainage tube hole suture improvement: Removal‐free stitches
Surgical method improvements aim to optimize the patient experience. The problem of healing of the drainage tube hole has not received attention and is of concern because it can plague patient recovery. In this article we report on how we have improved the method of suturing the drainage tube hole and explore the safety and effectiveness of this method. Between December 2017 to August 2018, 102 patients underwent thoracoscopic lung resection (single port or single utility port) using different methods of suturing drainage tube holes. The intervention group received improved methods with subcuticular and intradermal suture and removal‐free stitches, whilst the control group received a conventional mattress suture and fixed chest tube. A preset line was left to tie knots and close the hole after the removal of the chest tube. The stitches were removed 7–12 days after surgery. The baseline clinical features of the patients were subsequently analyzed. The objective and subjective conditions of scars were evaluated using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) at one month after surgery. The intervention group (n = 71) and control group (n = 31) had balanced baseline clinical characteristics. There were no significant differences between the two groups in terms of three‐day postoperative pain and postoperative hospital stay. In the intervention group, three patients (4.23%) had wound splitting that required re‐suturing, which was better than five patients (16.13%) in the control group (P < 0.05). The incidence of pleural fluid outflow, wound infection, post‐removal pneumothorax, chest tube prolapse and incisional hernia were not different between the two groups. We conclude that the objective and subjective evaluation results of scars were significantly different between the two groups (P < 0.05), and the experimental group was superior to the control group. A balanced result between aesthetic appearance and safety as regards video‐assisted thoracic surgery can be achieved through the chest tube hole improved suture method. This method also improves the patient's recovery experience.
- 1 July 2019
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 77 (7) , 1471-1479
Prognostic Impact of Postoperative Complications on Overall Survival in 287 Patients With Oral Cancer: A Retrospective Single-Institution Study
- 1 July 2019
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 77 (7) , 1471-1479
Prognostic Impact of Postoperative Complications on Overall Survival in 287 Patients With Oral Cancer: A Retrospective Single-Institution Study
- Open Access
- 25 April 2019
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 12 (1) , 1-24
Emerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Although increasing novel anticancer agents were innovated, how to translate and optimize these novel agents into clinical practice remains to be explored. Besides, toxicities and availability of these drugs in specific regions should also be considered during clinical determination. Herein, we summarize emerging agents including tyrosine kinase inhibitors, checkpoint inhibitors, and other potential immunotherapy such as chimeric antigen receptor T cell for non-small cell lung cancer attempting to provide insights and perspectives of the future in anticancer treatment.
- 25 April 2019
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 12 (1) , 1-24
Open AccessEmerging therapies for non-small cell lung cancer
Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Although increasing novel anticancer agents were innovated, how to translate and optimize these novel agents into clinical practice remains to be explored. Besides, toxicities and availability of these drugs in specific regions should also be considered during clinical determination. Herein, we summarize emerging agents including tyrosine kinase inhibitors, checkpoint inhibitors, and other potential immunotherapy such as chimeric antigen receptor T cell for non-small cell lung cancer attempting to provide insights and perspectives of the future in anticancer treatment.
- Open Access
- 17 April 2019
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 24 (9) , 1159-1165
Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network
Background: Computed tomography (CT) is essential for pulmonary nodule detection in diagnosing lung cancer. As deep learning algorithms have recently been regarded as a promising technique in medical fields, we attempt to integrate a well-trained deep learning algorithm to detect and classify pulmonary nodules derived from clinical CT images.Materials and Methods: Open-source data sets and multicenter data sets have been used in this study. A three-dimensional convolutional neural network (CNN) was designed to detect pulmonary nodules and classify them into malignant or benign diseases based on pathologically and laboratory proven results.Results: The sensitivity and specificity of this well-trained model were found to be 84.4% (95% confidence interval [CI], 80.5%–88.3%) and 83.0% (95% CI, 79.5%–86.5%), respectively. Subgroup analysis of smaller nodules (<10 mm) have demonstrated remarkable sensitivity and specificity, similar to that of larger nodules (10–30 mm). Additional model validation was implemented by comparing manual assessments done by different ranks of doctors with those performed by three-dimensional CNN. The results show that the performance of the CNN model was superior to manual assessment.Conclusion: Under the companion diagnostics, the three-dimensional CNN with a deep learning algorithm may assist radiologists in the future by providing accurate and timely information for diagnosing pulmonary nodules in regular clinical practices.Implications for Practice: The three-dimensional convolutional neural network described in this article demonstrated both high sensitivity and high specificity in classifying pulmonary nodules regardless of diameters as well as superiority compared with manual assessment. Although it still warrants further improvement and validation in larger screening cohorts, its clinical application could definitely facilitate and assist doctors in clinical practice.
- 17 April 2019
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 24 (9) , 1159-1165
Open AccessToward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network
Background: Computed tomography (CT) is essential for pulmonary nodule detection in diagnosing lung cancer. As deep learning algorithms have recently been regarded as a promising technique in medical fields, we attempt to integrate a well-trained deep learning algorithm to detect and classify pulmonary nodules derived from clinical CT images.Materials and Methods: Open-source data sets and multicenter data sets have been used in this study. A three-dimensional convolutional neural network (CNN) was designed to detect pulmonary nodules and classify them into malignant or benign diseases based on pathologically and laboratory proven results.Results: The sensitivity and specificity of this well-trained model were found to be 84.4% (95% confidence interval [CI], 80.5%–88.3%) and 83.0% (95% CI, 79.5%–86.5%), respectively. Subgroup analysis of smaller nodules (<10 mm) have demonstrated remarkable sensitivity and specificity, similar to that of larger nodules (10–30 mm). Additional model validation was implemented by comparing manual assessments done by different ranks of doctors with those performed by three-dimensional CNN. The results show that the performance of the CNN model was superior to manual assessment.Conclusion: Under the companion diagnostics, the three-dimensional CNN with a deep learning algorithm may assist radiologists in the future by providing accurate and timely information for diagnosing pulmonary nodules in regular clinical practices.Implications for Practice: The three-dimensional convolutional neural network described in this article demonstrated both high sensitivity and high specificity in classifying pulmonary nodules regardless of diameters as well as superiority compared with manual assessment. Although it still warrants further improvement and validation in larger screening cohorts, its clinical application could definitely facilitate and assist doctors in clinical practice.
- 1 April 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (4) , 726-731
Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement
- 1 April 2019
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (4) , 726-731
Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement